Albertsons Companies, Inc.

Albertsons Companies, Inc. (ACI) Market Cap

Albertsons Companies, Inc. has a market capitalization of $5.67B.

Price: $11.58

-0.02 (-0.17%)

Market Cap: 5.67B

NYSE · time unavailable

CEO: Susan Morris

Sector: Consumer Defensive

Industry: Grocery Stores

IPO Date: 2020-06-26

Website: https://www.albertsonscompanies.com

Albertsons Companies, Inc. (ACI) - Company Information

Market Cap: 5.67B|Sector: Consumer Defensive

Company Profile

Albertsons Companies, Inc., through its subsidiaries, operates in the food and drug retail industry in the United States. The company’s food and drug retail stores offer grocery products, general merchandise, health and beauty care products, pharmacy, vaccines, fuel, and other items and services. It also operates stores under various banners, including Albertsons, Safeway, Vons, Pavilions, Randalls, Tom Thumb, Carrs, Jewel-Osco, ACME, Shaw's, Star Market, United Supermarkets, Market Street, Haggen, Kings Food Markets, and Balducci's Food Lovers Market; and in-store pharmacies and branded coffee shops, fuel centers, distribution centers, and manufacturing facilities, as well as various digital platforms. Albertsons Companies, Inc. was founded in 1860 and is headquartered in Boise, Idaho.

Analyst Sentiment

63%
Buy

From 24 Active Polls

1Y Forecast: $13.36

▲ +15.4% Potential Upside

Consensus Target Metrics

Low Bound

$10

Median

$12

High Bound

$19

Average

$13

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$13.36
▲ +15.37% Upside
Low Target
$10.00
-14% Risk
Median Target
$12.00
4% Mid
High Target
$19.00
64% Max
Consensus
Hold
8 / 23 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Period EndingTrailing 12MJun 20, 2026Feb 28, 2026Nov 29, 2025Sep 6, 2025Jun 14, 2025Feb 22, 2025Nov 30, 2024Sep 7, 2024
Market Cap ($M)5,6726,8559,1249,75010,81312,15911,91111,48510,687
Enterprise Value ($M)21,07922,26324,22224,98125,83526,31825,79625,48924,605
Price to Earnings Ratio (P/E)144.7519.78-4.768.3315.8812.9417.137.1918.47
Price/Earnings-to-Growth Ratio (PEG)0.85-0.817.580.40128.615.98
Price to Sales Ratio (P/S)0.070.270.450.510.570.490.630.610.58
Price to Book Ratio (P/B)3.664.254.973.903.513.773.523.413.54
Price to Free Cash Flow Ratio (P/FCF)2.5019.9231.418.2124.1871.6143.47214.282740.19
Enterprise Value to Sales (EV/Sales)0.891.201.311.371.061.371.361.33
Enterprise Value to EBITDA (EV/EBITDA)7.0026.57149.9822.9228.0321.2228.8623.0728.32
Debt to Equity Ratio5.129.748.336.174.974.444.194.224.70

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ALBERTSONS COMPANY INC CLASS A (ACI) — Investment Overview

🧩 Business Model Overview

Albertsons is a large-format grocery and pharmacy retailer that converts consumer demand into retail margin through a centralized distribution footprint and store-level execution. The value chain runs from upstream sourcing (manufacturers and wholesalers) to Albertsons’ logistics and merchandising, then to point-of-sale at owned/leased stores and pharmacy counters. Monetisation is primarily driven by (1) product gross margin (including mix effects such as higher-share private label and pharmacy), (2) operating leverage from running a dense store network, and (3) capturing value from loyalty and promotional mechanics that reinforce shopping frequency and basket size.

💰 Revenue Streams & Monetisation Model

Revenue is predominantly transactional and comes from grocery baskets, pharmacy services, and fuel/other ancillary offerings. The margin architecture is best understood as a blend of:

  • Grocery gross margin: supported by purchasing scale, category management, and assortment discipline; challenged by commodity and freight cycles.
  • Private label monetisation: typically improves margin resilience versus branded-only competitors, assuming stable consumer acceptance and disciplined quality/cost controls.
  • Pharmacy contribution: adds both margin and traffic-generation; it also provides a more recurring element through prescription volumes versus core grocery.
  • Operating cost absorption: distribution density, store productivity, and labor/technology efficiency determine whether gross profit translates into earnings.

Overall profitability is most sensitive to (1) product mix and promotional intensity, (2) shrink and shrink-related controls, and (3) labor and occupancy costs relative to sales throughput.

🧠 Competitive Advantages & Market Positioning

Albertsons’ competitive positioning is grounded in scale/distribution leverage and private label resistance. These factors can help defend share and margin in a mature, price-competitive retail market, even though consumer switching costs are low.

  • Scale & distribution leverage: Albertsons benefits from purchasing power and logistics optimization that can lower delivered cost per unit and improve inventory availability—critical in grocery where out-of-stocks and waste directly impair profitability.
  • Private label economics: maintaining cost-advantaged private label programs can reduce dependence on branded pricing power. Competitors face friction in matching both cost and quality at scale.
  • Store network density & service mix: the ability to pair grocery with pharmacy service lines supports traffic durability and improves sales productivity per store footprint.

Competitive benchmarking (industry peers):

  • Kroger Co. (KR): also emphasizes scale and private label, running a similar grocery + pharmacy model. Albertsons competes on regional store footprint, merchandising execution, and distribution cost discipline.
  • Walmart (WMT): competes through massive general merchandise scale and everyday-low-price pricing power. The differentiation tends to be category assortment depth, grocery freshness execution, and pharmacy/service adjacency rather than pure pricing volume.
  • Target (TGT): overlaps in discretionary and certain grocery-adjacent categories but is structurally different in store format and assortment strategy. Albertsons’ advantage centers on being a dedicated grocery/pharmacy operator with higher grocery share of wallet.

Compared with these rivals, Albertsons’ industry focus remains squarely on food-at-home and pharmacy-enabled grocery, where distribution execution and private label economics can be more decisive than brand-led differentiation.

🚀 Multi-Year Growth Drivers

Growth in grocery retail is typically achieved through a mix of modest traffic expansion, share shifts among value-conscious consumers, and margin management. Over a 5–10 year horizon, the most durable drivers include:

  • Share capture via value positioning: private label expansion and tighter merchandising can support share resilience when consumer budgets tighten.
  • Operating efficiency & productivity: technology-enabled inventory accuracy, labor scheduling, and better promotional calibration can improve earnings quality without relying on top-line growth alone.
  • Pharmacy and adjacent services: prescriptions and pharmacy-driven basket effects can support steadier contribution margins than pure grocery.
  • Omnichannel execution: pickup/delivery capabilities can increase customer convenience and basket size, provided fulfillment costs are tightly controlled.
  • Category mix optimization: higher-margin categories (where demand supports it) and improved shrink controls can expand gross profit dollars through cycle.

While the grocery TAM is mature, the practical addressable opportunity is less about market size and more about capturing share and reducing cost-to-serve through scale execution.

⚠ Risk Factors to Monitor

  • Margin pressure from competitive pricing: aggressive promotional cycles can compress gross margin and offset private label benefits.
  • Input cost and logistics volatility: commodities, freight, and labor inflation can create earnings drawdowns if price/mix cannot adjust fast enough.
  • Regulatory and antitrust scrutiny: store network changes, pharmacy regulations, and consolidation-related constraints can affect strategic flexibility.
  • Labor and occupancy dynamics: wage rates, scheduling complexity, and lease terms influence store-level operating leverage.
  • Execution risk in omnichannel: delivery/pickup expansion can raise fulfillment costs and working-capital needs if scale economics do not materialize.
  • Supply chain and shrink: inventory accuracy, theft prevention, and food waste discipline are structural to grocery economics.

📊 Valuation & Market View

Equity valuation for grocery retailers often reflects the market’s assessment of (1) sustainable operating margin, (2) free cash flow conversion, and (3) balance-sheet risk. Market participants commonly frame value using EV/EBITDA and earnings/FCF multiples, with key qualitative adjustments for:

  • Same-store sales quality (mix and promotional intensity versus purely unit volume)
  • Gross margin stability driven by private label penetration and procurement discipline
  • Operating expense leverage from distribution productivity and store labor efficiency
  • Working-capital efficiency (inventory turns and cash conversion)
  • Capital intensity associated with store refresh, technology, and logistics capabilities

🔍 Investment Takeaway

Albertsons’ long-term thesis centers on defending profitability in a structurally competitive market through scale/distribution leverage and private label monetisation, supported by a grocery-plus-pharmacy model that can stabilize traffic and contribution margins. The investment case is strongest when operational execution sustains gross profit dollars and cost-to-serve improvement offsets pricing and cost volatility.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for ACI.

globenewswire.com2026-07-30

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Albertsons Companies (ACI)

Albertsons shares were falling nearly 22% after the Company's earnings miss and sharp FY 2026 guidance cut. Albertsons shares were falling nearly 22% after the Company's earnings miss and sharp FY 2026 guidance cut.

zacks.com2026-07-29

How Albertsons Is Betting on AI, Digital Growth and Loyalty Scale

Albertsons is using AI, digital growth and its 51.2 million-member loyalty program to boost personalization, but execution remains key to turning investments into earnings.

zacks.com2026-07-29

Is ACI Stock a Deep Value Opportunity After Its Steep 2026 Sell-Off?

Albertsons trades near multi-year valuation lows, but weaker earnings, lower guidance and margin pressure complicate the deep-value case.

zacks.com2026-07-29

Why Albertsons Faces a High-Stakes Fiscal 2026 Reset After Weak Q1

ACI faces a pivotal fiscal 2026 as lower guidance and ACI Edge aim to offset weak grocery trends while digital and pharmacy remain bright spots.

businesswire.com2026-07-29

ACI Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Albertsons Companies (ACI)

NEW YORK--(BUSINESS WIRE)--A 22% drop hit Albertsons Companies (NYSE: ACI) shares on July 23, 2026, after the Company cut FY 2026 adjusted EPS guidance to $1.75-$1.85 from $2.22-$2.32. Investors who held ACI through the guidance cut and suffered losses should act promptly. ACI shareholders who lost money are encouraged to submit their loss details now or contact Levi & Korsinsky, LLP | (212) 363-7500 | www.zlk.comOn April 14, 2026, CFO Sharon McCollam told investors that adjusted EPS was exp.

prnewswire.com2026-07-28

ACI SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Albertsons Companies

Albertsons investors who lost money after the July 23, 2026 drop may have questions about proxy statements describing executive award timing and material non-public information policies. NEW YORK, July 28, 2026 /PRNewswire/ -- On July 23, 2026, Albertsons Companies (NYSE: ACI) shares fell roughly 22% after Q1 FY 2026 results missed expectations and the Company cut full-year adjusted EPS guidance.

247wallst.com2026-07-28

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Boston Scientific, Clorox, CrowdStrike, Exxon Mobil, Honeywell International, Intuit, Intuitive Surgical, Levi Strauss, and More

Wall Street analysts are busy reshuffling their ratings ahead of the Fed meeting, with surprise double-upgrades, dramatic target cuts, and fresh initiations spanning surgical robots to cybersecurity. Find out which names made the biggest moves today.

businesswire.com2026-07-28

ACI Worldwide and dLocal Bring Latin America's Leading Local Payment Methods to Global Merchants

OMAHA, Neb. & MONTEVIDEO, Uruguay--(BUSINESS WIRE)--ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology, and dLocal (NASDAQ: DLO), the leading payment platform connecting global merchants to emerging markets, today announced a strategic partnership that gives global merchants immediate and seamless access to leading local payment methods in Brazil and Mexico through the ACI Payments Orchestration Platform, with Argentina, Chile, Colombia and Peru planned for future.

gurufocus.com2026-07-27

ACI Investors Have Opportunity to Join Albertsons Companies, Inc. Fraud Investigation with SBS Law

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv

businesswire.com2026-07-27

ACI Investors Have Opportunity to Join Albertsons Companies, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $ACI--ACI Investors Have Opportunity to Join Albertsons Companies, Inc. Fraud Investigation with SBS Law.

prnewswire.com2026-07-27

Albertsons Companies Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Albertsons Companies (ACI)

Albertsons investors who relied on the Company's fiscal 2026 sales and earnings guidance faced losses after Albertsons reduced its full-year outlook, reported disappointing quarterly results, and shares fell nearly 22%. NEW YORK, July 27, 2026 /PRNewswire/ -- Albertsons Companies (NYSE: ACI) shares fell roughly 22% on July 23, 2026 after Q1 FY 2026 results missed expectations and the Company reduced its full-year adjusted EPS outlook.

seekingalpha.com2026-07-27

Albertsons: The Turnaround Is Priced For Failure (Rating Upgrade)

Albertsons Companies is rated Strong Buy, with current valuation implying a significant discount even under conservative turnaround assumptions. ACI's ACI Edge initiative targets $200 million in annual run-rate benefits by fiscal 2027, supporting cost savings, reinvestment, and strategic priorities. Private label growth and data-driven insights position ACI for long-term differentiation, especially as consumer trade-downs accelerate in the near-term.

businesswire.com2026-07-27

Tom Thumb, Albertsons and Randalls Partner with CeeDee Lamb to Fight Childhood Hunger This Back-to-School Season

ARLINGTON, Texas--(BUSINESS WIRE)--Tom Thumb, Albertsons and Randalls announced the Back-to-School Nourishing Neighbors Campaign, a fundraising effort to help fight childhood hunger.

247wallst.com2026-07-27

Here Are Monday’s Top Wall Street Analyst Research Calls: Alphabet, Clean Harbors, Ford, Huntington Bancshares, Rivian, Rocket Lab, Terawulf, Vale, Warner Bros. Discovery, and More

Wall Street analysts are reshuffling their bets ahead of the busiest earnings week of the quarter, and the moves span everything from legacy automakers to crypto miners to space launch companies. Find out which names just got upgraded, downgraded, or picked up for the first time.

foxbusiness.com2026-07-24

Albertsons warns of softer grocery demand as consumers pull back

Albertsons cut its annual outlook after comparable grocery sales declined, while digital and pharmacy growth helped offset pressure in its core business.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-20

"ACI reported 2026-06-20 quarter revenue of $24.94B and net income of $84.7M (EPS $0.17). On a YoY basis versus 2025-06-14, revenue was roughly flat/down slightly (+0.2%), while net income improved from $236.4M to $84.7M (net income -64.2%), indicating significantly lower profitability year-over-year. QoQ, revenue rose from $20.25B (2026-02-28) to $24.94B (+23.3%), but net income swung from a loss of -$480.8M to +$84.7M, a large improvement sequentially. Margins improved slightly on gross margin (26.6% vs 25.1% QoQ), yet overall net margin remains very thin at ~0.34%. Interest expense remained steady at ~$167M, and operating leverage appears volatile given the swing from a large Q4 loss to a Q1 profit. Operating cash flow was strong at $866.3M, producing positive free cash flow of $344.2M despite capex of $522.1M. Shareholder cash returns were mixed: buybacks continued (-$224.9M) alongside dividends paid (-$84.0M). Balance sheet resilience is mixed—equity is low at ~$1.61B and leverage remains high (total debt ~$15.7B; net debt ~$15.4B), though cash increased to ~$293M. Total shareholder returns are currently challenged: the stock is down ~21.0% over 1 year, which would pressure total return despite buybacks and a ~1.2% dividend yield."

Revenue Growth

Neutral

QoQ revenue increased from $20.25B to $24.94B (+23.3%). YoY revenue was roughly flat, from $24.88B to $24.94B (+0.2%).

Profitability

Neutral

Net income improved QoQ (-$480.8M to +$84.7M) but deteriorated YoY ($236.4M to $84.7M, -64.2%). Net margin remains very low (~0.34%) and operating margin is still thin (~1.06%).

Cash Flow Quality

Positive

Operating cash flow was $866.3M and free cash flow $344.2M in the quarter, both positive. Dividends paid were $84M; buybacks were $225M. However, payout ratio metrics look high given low earnings levels.

Leverage & Balance Sheet

Caution

Leverage is elevated: total debt ~$15.7B and net debt ~$15.4B, with thin equity ($1.61B). Equity rose modestly QoQ, but balance-sheet resilience remains constrained.

Shareholder Returns

Caution

Buybacks and dividends were present (-$224.9M buybacks; -$84.0M dividends). Total return is tempered by weak stock performance (1Y -21.0%) and modest dividend yield (~1.2%).

Analyst Sentiment & Valuation

Neutral

Consensus price target is $14.09 vs current $16.70 (implied downside). Valuation multiples appear elevated in the provided ratios, with limited support from earnings power given thin margins.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Q1 2026 results were below expectations with identical sales down 0.8% and adjusted EPS of $0.42. Management attributed most performance softness to pharmacy-linked and macro headwinds: ~100 bps from the Inflation Reduction Act and 50 bps from deflation; excluding these, identical sales rose ~0.7% led by pharmacy scripts and digital growth. Gross margin fell 23 bps YoY (excluding fuel and LIFO) to 26.6%, driven largely by digital mix while productivity offset most customer-value investments. SG&A rate increased 42 bps (excluding fuel) from rent/occupancy, litigation, transformation costs, and depreciation. The centerpiece is ACI Edge: simplifying the operating model (11 divisions to 4 regions) and centralizing center-store merchandising to accelerate decisions, improve category/promo execution, and fund reinvestment via productivity. FY2026 guidance reflects a more cautious demand outlook while maintaining long-term earnings power confidence.

AI IconGrowth Catalysts

  • ACI Edge operating model: 11 divisions to 4 regions (California, West, South, East/central) plus centralized center-store merchandising to speed decisions and execution
  • Digital customer experience: AI-powered conversational search/planning tools driving higher engagement and basket size; Flash Delivery fastest-growing digital segment
  • Digital profitability milestone: e-commerce profitable in Q1 across first-party and third-party
  • Pharmacy: outsized growth in scripts/immunizations/clinical services despite IRA and branded-to-generic mix pressure; profitability improving on a stand-alone basis
  • Media monetization expansion: on-site revenue up sharply; “branded entertainment” (shopper inform content) and AI conversational search sponsored product discovery

Business Development

  • Expanded partnerships with AI providers: Google, OpenAI, Microsoft
  • Merchandising intelligence vendor collaboration: AI tools expanded into broader planning processes with selected vendor partners

AI IconFinancial Highlights

  • Reported Q1 identical sales -0.8%; adjusted EBITDA $1.013B; adjusted EPS $0.42
  • Headwinds impacting reported results: ~100 bps from Inflation Reduction Act (pharmacy) and 50 bps from deflation; excluding these, identical sales +~0.7%
  • Gross margin: 26.6%, down 23 bps YoY (excluding fuel and LIFO); mix impact from outsized digital growth; productivity benefits mostly offset surgical customer-value investments
  • Gross margin also reflected favorable rate impact associated with lower pharmacy IRA sales
  • SG&A rate: excluding fuel, +42 bps YoY; driven by rent/occupancy, merger-related litigation, transformation costs, and depreciation; partially offset by lower employee costs; also unfavorable rate impact from lower pharmacy IRA sales
  • Q1 interest expense: +$25M to $167M due to higher borrowings and slightly higher average rates
  • Productivity delivery: adjusted SG&A approximately flat (in dollars) reflecting productivity benefits

AI IconCapital Funding

  • Q1 capital expenditures: $522M (store modernization incl. 4 new stores) plus technology/AI investment
  • Returned >$300M to shareholders in Q1: ~$225M share repurchases under existing $2B authorization; $84M dividends
  • Balance sheet: net debt to adjusted EBITDA 2.3x, cited as providing ample financial flexibility
  • FY2026 capital allocation: ~ $600M of share repurchases expected during fiscal 2026

AI IconStrategy & Ops

  • ACI Edge implementation progress: leadership appointments complete; center-store centralization begun; workstreams progressing across merchandising, sourcing, supply chain, and overhead
  • Technology/AI operating priorities (enterprise AI): digital customer experience, merchandising intelligence, labor optimization (enterprise-wide rollout early 2027), and supply chain optimization (forecasting/inventory/replenishment; unified AI ordering platform)
  • Productivity execution: on track to realize >1/3 of the 3-year $2B productivity target in fiscal 2026; “savings building through fiscal 2026 and majority realized in fiscal 2027”
  • Customer value proposition investments: “surgically invest” in price perception, fresh, personalization, and convenience; funded through productivity to improve traffic, units, loyalty over time

AI IconMarket Outlook

  • FY2026 identical sales outlook: -0.5% to -1.5% and 0% to +1% excluding expected 150 bps full-year pharmacy IRA headwind
  • FY2026 adjusted EBITDA: $3.55B to $3.625B
  • FY2026 adjusted EPS: $1.75 to $1.85 per share, including ~ $600M of share repurchases
  • FY2026 effective tax rate: 24% to 25%
  • FY2026 capital expenditures: $1.9B to $2.0B
  • Centralized merchandising completion timing discussed in Q&A: complete in “spring, early summer” of next year

AI IconRisks & Headwinds

  • Near-term demand pressure: lower-income consumer softness; industry unit declines and macro pressures; customers trading down/value packaging and shifting to cheaper proteins
  • Pharmacy IRA impacts: near-term pharmacy IDs pressured; reported results impacted by ~150 bps full-year expectation for FY2026 and ~100 bps in Q1 already
  • Gross margin headwinds from digital mix: outsized digital growth increased mix pressure despite productivity offsetting surgical investments
  • SG&A inflation: rent/occupancy, transformation, depreciation; additional pressure from lower pharmacy IRA sales rate impacts
  • Supplier cost increases: expected incremental pressure in the second half of the year; worst-case product acceptance decisions if negotiations fail

Q&A: Analyst Interest

  • Topic: Price investment positioning and whether management is disclosing targeting mechanics or pursuing alternatives; Management’s detailed response: Susan described the price investments as “targeted market-specific” actions tied to price perception plus fresh/personalization/convenience, funded via productivity. She said management learned elasticities from prior focus markets and declined to disclose an index vs peers. Strategic alternatives were not the primary discussion.
  • Topic: Centralized merchandising enhancements vs prior buying initiative and timeline; Management’s detailed response: Susan explained this builds on “buying better together” that used AI-driven tools and process work over ~two years. The enhancement is stronger category/assortment and price-promo decisions from center while remaining surgical locally. Timing is “complete somewhere in spring, early summer of next year.”
  • Topic: Consumer/basket pressure by category plus supplier cost-increase timing and negotiation stance; Management’s detailed response: Susan stated pressure is most pronounced in lowest-income customers, with shifts to private label, value-packaging trade-downs, and cheaper proteins; higher-end customers show more resilience. For supplier increases, she expects incremental pressure in the second half, with first response pushing back, then negotiations, and worst-case decisions on accepting products.

Sentiment: MIXED

Note: This summary was synthesized by AI from the ACI Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for ACI.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (ACI)

© 2026 Stock Market Info — Albertsons Companies, Inc. (ACI) Financial Profile